Abiopharma

🔍 Lubner David Charles (Executive)

Company: Arcellx, Inc. (ACLX)

Report Date: 2026-01-20

Detailed Transactions and Holdings:

• Acquired 6,000 shares of Common Stock at $6.28 per share (Direct)
  Date: 2026-01-20 | Code: M | equity_swap_involved: false | shares_owned_after: 27,659.00 | transaction_form_type: 4
• Sold 6,000 shares of Common Stock at $75.0 per share (Direct)
  Date: 2026-01-20 | Code: S | equity_swap_involved: false | shares_owned_after: 21,659.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,000 shares of Stock Option (right to buy) at $6.28 per share (Derivative)
  Date: 2026-01-20 | Code: M | Expires: 2031-06-09 | equity_swap_involved: false | shares_owned_after: 59,405.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 29, 2025.
• F2: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean June 9, 2021.